8-K: Zentalis Pharmaceuticals Focuses Azenosertib Development on Cyclin E1+ Ovarian Cancer After Promising Trial Results

Zentalis Pharmaceuticals will prioritize the development of azenosertib for patients with Cyclin E1-positive platinum-resistant ovarian cancer (PROC) following encouraging clinical trial results.

Summary

• Zentalis Pharmaceuticals is shifting its focus to developing azenosertib as a monotherapy for patients with Cyclin E1-positive platinum-resistant ovarian cancer (PROC).
• The company has aligned with the FDA on the design of the DENALI Part 2 study, which will evaluate azenosertib in this patient population.
• DENALI Part 2 will have a seamless enrollment across Parts 2a and 2b, with Part 2a designed to confirm the optimal dose of 400mg QD 5:2, and Part 2b enrolling approximately 70 patients at a single dose informed by Part 2a results.
• The company plans to initiate enrollment for DENALI Part 2 in the first half of 2025 and expects to release topline data by the end of 2026.
• Clinical results from the ZN-c3-001 study showed an objective response rate (ORR) of 34.8% and a median duration of response (mDOR) of 5.2 months in Cyclin E1-positive PROC patients treated with azenosertib at 300mg intermittent dosing.
• In the MAMMOTH study, Cyclin E1-positive patients treated with azenosertib at 400mg QD 5:2 had an ORR of 31.3% and an mDOR of 4.2 months.
• DENALI Part 1b showed an ORR of 34.9% in response-evaluable Cyclin E1-positive PROC patients and an ORR of 31.3% in the intent-to-treat population, with an mDOR of approximately 5.5 months.
• Azenosertib has demonstrated a manageable safety profile across multiple studies, with low rates of Grade 3+ gastrointestinal treatment-related adverse events and hematological toxicity.
• The company has decided not to advance the combination of azenosertib with niraparib or the dose expansion phase of the ZN-c3-016 study in colorectal cancer due to resource prioritization and an evolving treatment landscape.

Sentiment

Score: 8

Explanation: The document presents positive clinical data and a clear development path for azenosertib, with a focus on a specific patient population. The company has also extended its cash runway, which is a positive sign. However, there are some risks and uncertainties associated with drug development, which temper the overall sentiment.

Positives

• Azenosertib has shown promising anti-tumor activity in Cyclin E1-positive PROC patients across multiple studies.
• The company has aligned with the FDA on the design of the DENALI Part 2 study, which could lead to accelerated approval.
• Azenosertib has demonstrated a manageable safety profile with low rates of severe adverse events.
• The company has extended its cash runway into late 2027, beyond the anticipated topline data readout from DENALI Part 2.
• Cyclin E1 has been identified as a predictive biomarker for response to azenosertib.

Negatives

• The company is not proceeding with the development of azenosertib in combination with niraparib.
• The company is not advancing the dose expansion phase of the ZN-c3-016 study in colorectal cancer.
• There were some treatment-related Grade 5 events reported across the studies.
• Discontinuation rates in the DENALI study were higher than in previous studies, although the company plans to improve this in future trials.

Risks

• The company's limited operating history may make it difficult to evaluate its current business and predict future success.
• The company has and expects to continue to incur significant losses.
• The company may need additional funding, which may not be available.
• The outcome of preclinical testing and early trials may not be predictive of the success of later clinical trials.
• Potential unforeseen events during clinical trials could cause delays or other adverse consequences.
• There are risks relating to the regulatory approval process and the possibility of not obtaining U.S. or international marketing approval.
• The company's product candidates may cause serious adverse side effects.
• The company relies on third parties and may face challenges in maintaining collaborations.
• The company faces significant competition and risks relating to intellectual property.

Future Outlook

The company plans to initiate enrollment of the DENALI Part 2 study in the first half of 2025 and expects to disclose topline data by the end of 2026. The company believes that DENALI Part 2, if successful, has the potential to support an accelerated approval for azenosertib in Cyclin E1-positive PROC.

Management Comments

• Ingmar Bruns, M.D., Chief Medical Officer, stated that the monotherapy data showed a meaningful and consistent improvement in responses compared to historical data.
• Julie Eastland, Chief Executive Officer, expressed pleasure with the azenosertib results and believes the company has a clear path to advancing the product to patients.
• Management believes that the therapeutic and commercial opportunity in the Cyclin E1+ PROC population is substantial.

Industry Context

The focus on a biomarker-defined patient population aligns with the growing trend in oncology towards precision medicine. The company is targeting a specific subset of ovarian cancer patients with a high unmet need, where current standard of care has limited efficacy. The recent launch of a therapy in biomarker selected PROC demonstrates the large commercial opportunity.

Comparison to Industry Standards

• The objective response rates (ORR) observed in the azenosertib trials, particularly in the Cyclin E1+ PROC population, are higher than the 4-13% ORR typically seen with standard of care chemotherapy in this setting.
• The company is comparing their results to historical data from standard of care chemotherapy, not head-to-head trials, so caution should be exercised when comparing data across these studies.
• The company is also comparing their results to the recently approved therapy in biomarker selected PROC, which has shown ORR of 32-42%.
• Other WEE1 inhibitors have been developed, but Zentalis believes azenosertib has a potentially best-in-class safety profile.

Stakeholder Impact

• Shareholders: The positive clinical data and focused development strategy could lead to increased shareholder value.
• Patients: The development of azenosertib could provide a new treatment option for patients with Cyclin E1-positive platinum-resistant ovarian cancer.
• Employees: The focused strategy and extended cash runway could provide job security and opportunities for growth.
• Analysts: The data and development plans provide a clear picture of the company's strategy and potential.

Next Steps

• Initiate enrollment of the DENALI Part 2 study in the first half of 2025.
• Disclose topline data from DENALI Part 2 by the end of 2026.
• Present updated data at medical meetings in the future.
• Continue development of azenosertib in other tumor types and combinations.

Key Dates

Keywords

Azenosertib, Ovarian Cancer, Cyclin E1, WEE1 Inhibitor, Platinum-Resistant, PROC, Clinical Trial, Monotherapy, FDA, Biomarker, DENALI, MAMMOTH, ZN-c3-001, ZN-c3-005, ZN-c3-006